Study of ARQ 197 in Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in
hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the
recommended dose of ARQ 197 in advanced HCC patients.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.